+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement



Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement



Neuropharmacology 62(7): 2288-2298



The reinforcing effects of nicotine are mediated in part by brain dopamine systems. Serotonin, acting via 5-HT(2A) and 5-HT(2C) receptors, modulates dopamine function. In these experiments we examined the effects of the 5-HT(2C) receptor agonist Ro60-0175 and the 5-HT(2A) receptor antagonist (M100907, volinanserin) on nicotine self-administration and reinstatement of nicotine-seeking. Male Long-Evans rats self-administered nicotine (0.03 mg/kg/infusion, IV) on either a FR5 or a progressive ratio schedule of reinforcement. Ro60-0175 reduced responding for nicotine on both schedules. While Ro60-0175 also reduced responding for food reinforcement, response rates under drug treatment were several-fold higher than in animals responding for nicotine. M100907 did not alter responding for nicotine, or food, on either schedule. In tests of reinstatement of nicotine-seeking, rats were first trained to lever press for IV infusions of nicotine; each infusion was also accompanied by a compound cue consisting of a light and tone. This response was then extinguished over multiple sessions. Injecting rats with a nicotine prime (0.15 mg/kg) reinstated responding; reinstatement was also observed when responses were accompanied by the nicotine associated cue. Ro60-0175 attenuated reinstatement of responding induced by nicotine and by the cue. The effects of Ro60-0175 on both forms of reinstatement were blocked by the 5-HT(2C) receptor antagonist SB242084. M100907 also reduced reinstatement induced by either the nicotine prime or by the nicotine associated cue. The results indicate that 5-HT(2C) and 5-HT(2A) receptors may be potential targets for therapies to treat some aspects of nicotine dependence.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052888981

Download citation: RISBibTeXText

PMID: 22342986

DOI: 10.1016/j.neuropharm.2012.01.023


Related references

The 5-HT2C receptor agonist Ro60-0175 reduces cocaine self-administration and reinstatement induced by the stressor yohimbine, and contextual cues. Neuropsychopharmacology 33(6): 1402-1412, 2007

Influence of the 5-HT2C receptor antagonist SB242,084 on behaviour produced by the 5-HT2 agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine. British Journal of Pharmacology 133(4): 459-466, 2001

Antagonizing 5-HT₂A receptors with M100907 and stimulating 5-HT₂C receptors with Ro60-0175 blocks cocaine-induced locomotion and zif268 mRNA expression in Sprague-Dawley rats. Behavioural Brain Research 240: 171-181, 2013

Injection of the 5-HT2C receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Neuropsychopharmacology 29(2): 308-318, 2003

Is the apparent antipsychotic action of the 5-HT2A receptor antagonist M100907 counteracted by concomitant 5-HT2C receptor antagonist treatment?. Society for Neuroscience Abstracts 24(1-2): 1369, 1998

Differential effects of the 5-HT2A receptor antagonist MDL100,907 and the 5-HT2C receptor antagonist SB242,084 on cocaine induced locomotor activity, cocaine self-administration and cocaine induced reinstatement of responding. Society for Neuroscience Abstracts 27(1): 1176, 2001

(1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. European Journal of Pharmacology 615(1-3): 1-9, 2009

Characterisation of the 5-HT2C receptor agonist RO 60-0175 in cells expressing the human 5-HT2C receptor. Society for Neuroscience Abstracts 24(1-2): 1371, 1998

The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice. Journal of Neural Transmission 106(2): 123-129, 1999

Effects of the serotonin 5-HT2A/2C receptor agonist DOI and of the selective 5-HT2A or 5-HT2C receptor antagonists EMD 281014 and SB-243213, respectively, on sleep and waking in the rat. European Journal of Pharmacology 553(1-3): 163-170, 2006

Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding. Neuropsychopharmacology 27(4): 576-586, 2002

Effects of RO 60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety. European Journal of Pharmacology 387(2): 197-204, Jan 10, 2000

Effects of the 5-HT2A receptor antagonist, MDL 100,907 and the 5-HT2C receptor antagonist, SB 206553, on lordosis responding of female rats. Society for Neuroscience Abstracts 24(1-2): 1924, 1998

Effects of the GABAB receptor agonist CGP44532 on nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour. Journal of Psychopharmacology 17(Suppl. 3): A31, 2003

The effects of D-fenfluramine and the selective 5-HT2C receptor agonist RO 60-0175 in the elevated zero-maze, an animal model of anxiety. Society for Neuroscience Abstracts 24(1-2): 943, 1998